A case study of glycogen storage disease type Ia presenting with multiple hepatocellular adenomas: an analysis by gadolinium ethoxybenzyl-diethylenetriamine-pentaacetic acid magnetic resonance imaging

Xiaoming Li1#, Hui Jing2#, Lin Cheng1, Jie Xia3, Jian Wang1, Qing Li4, Chen Liu1, Ping Cai1

1Department of Radiology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China; 2Department of Radiology, Shan Xi Medical University, Taiyuan, China; 3Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China; 4Magnetic Resonance Collaborations, Siemens Healthcare Ltd., Shanghai, China

#These authors contributed equally to this work.

Correspondence to: Chen Liu; Ping Cai. Department of Radiology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China. Email: liuchen@aifmri.com; 530305942@qq.com.

Abstract: Glycogen storage disease type Ia (GSD Ia) is a rare disease caused by a deficiency of hepatic glucose-6-phosphatase (G6Pase). Here, we report a 17-year-old Chinese boy with GSD Ia. Clinical manifestations of the patient included hepatomegaly, growth retardation, doll face, and biochemical abnormalities, including hypoglycaemia, hyperuricaemia, and hyperlipidaemia. The computed tomography (CT) and gadolinium ethoxybenzyl-diethylenetriamine-pentaacetic acid (Gd-EOB-DTPA) magnetic resonance imaging (MRI) revealed multiple masses in the left and right hemiliver. These masses presented as different dynamic enhanced patterns in the Gd-EOB-DTPA MRI. In addition, a large amount of glycogen deposit was detected in the liver tissue biopsy. Liver puncture confirmed that the masses were hepatocellular adenomas (HCAs). Genetic analyses confirmed the presence of liver metabolic disease, and the final clinical diagnostic was GSD Ia. The patient’s clinical manifestations were significantly improved following regular treatment with raw corn starch for 9 months. Unfortunately, it was suspected that parts of the adenoma had undergone malignant transformation.

Keywords: Glycogen storage disease (GSD); gadolinium ethoxybenzyl-diethylenetriamine-pentaacetic acid (Gd-EOB-DTPA); magnetic resonance imaging (MRI); adenoma; gene


doi: 10.21037/qims-20-746

View this article at: http://dx.doi.org/10.21037/qims-20-746

Introduction

Glycogen storage disease type Ia (GSD Ia) is an extremely rare autosomal recessive inherited disorder affecting glycometabolism, with a prevalence of 1 in 100,000 (1). Deficiency of the enzyme glucose 6-phosphatase (G6Pase) leads to abnormal glycogen metabolism, which then causes abnormal deposits of glycogen in the endoplasmic reticulum cavity. European research guidelines recommend that the diagnosis of GSD Ia should be based on clinical manifestations, imaging, and abnormal biochemical indicators (2). Diet and adjuvant drug therapy are the main forms of treatment for GSD type I. The objective is to maintain blood glucose levels and prevent long-term complications, including the development of hepatocellular adenomas (HCAs) and hepatocellular carcinomas (HCCs) (3). Although the use of magnetic resonance imaging (MRI) in
the detection of HCAs has been reported in the literature (4-6), to our knowledge, this is the first case to include a comprehensive dataset, including clinical signs, laboratory tests, imaging manifestations, pathology, gene sequencing, and follow-up results.

**Case presentation**

A 17-year-old boy presented with growth retardation and was initially admitted for short stature. Physical examination revealed weight loss, lack of male sexual development, facial signs of chronic liver disease (**Figure 1A**), and an enlarged liver. Fasting blood glucose levels (3.57 mmol/L) were slightly decreased. Platelet count (374×10^9 g/L), alkaline phosphatase (274 IU/L), glutamyl transpeptidase (233 IU/L), glutamic oxaloacetic transaminase (115 IU/L), alanine transaminase (71 IU/L), triglycerides (5.76 mmol/L), total cholesterol (6.54 mmol/L), lactate dehydrogenase (115 IU/L), albumin (51.20 g/L), anion gap (24 mmol/L), and uric acid (477 μmol/L) levels were all elevated. He tested positive for ketone bodies. Other indicators, such as alpha fetoprotein and abnormal prothrombin, were normal. He also tested positive for hepatitis B virus (HBV) markers and had been undergoing antiretroviral therapy for the past 16 years.

The contrast-enhanced abdominal computed tomography (CT) examination at the time of admission (**Figure 1B**) showed multiple low-density nodules, and the largest nodule was located in segment II of the liver. Abdominal CT scans

---

**Figure 1** The computed tomography (CT) and magnetic resonance imaging (MRI) images of a 17-year-old male patient with Glycogen storage disease type Ia and hepatocellular adenomas. (A) A photograph of the patient presenting with doll face, growth retardation, and absence of male sexual development. (B,C,D,E,F) The contrast-enhanced CT results performed at time intervals of 15 months. Examination on July 1, 2015 showed a low-density nodule in segment II (white arrow, B). At the patient's second examination, the number and diameter of the nodules had increased (white arrows, C). The lesion (no. 2, white triangle, D) was hyperintense on T2WI. The lesion was hyperintense on in-phase analysis (E). Perilesional signal (white triangles) was decreased on opposed-phase analysis (F). (G,H,I) The dynamic enhanced MRI. The lesion was significantly enhanced in the arterial phase (white arrow, G), and persisted to the delayed phase (white arrow, H) in comparison with adjacent hepatocytes. (I) Coronary hepatobiliary phase (HBP; white arrow) showed enlarged liver volume, and the nodule was hypointense but mixed with a slightly hyperintense interior.
performed 15 months later (Figure 1C) revealed that the number and diameter of the nodules had increased.

The gadolinium ethoxybenzyl-diethylenetriamine-pentaacetic acid (Gd-EOB-DTPA) MRI (Figure 1D,E,F,G,H,I) revealed an enlarged liver with fat infiltration. Thirteen abnormal rounded nodules were found in the left and right hemiliver with different diameters and signal features. Details of the Gd-EOB-DTPA MRI findings are shown in Table 1. These hypervascular features are commonly observed in different histological types of liver tumors (7). Therefore, to establish an exact diagnosis of GSD, systematic clinical characteristics including the enlarged liver, developmental retardation, and laboratory examinations were used together with the same hypervascular MRI imaging presentations.

Liver puncture was performed vertically into the liver (about 3 cm deep), and soft liver tissues (1 cm) were rapidly extracted. Staining of the liver tissues with periodic acid-Schiff (PAS) showed large amounts of glycogen deposition in the hepatocytes (Figure 2A). The pathology of one of the nodules was confirmed to be HCA (Figure 2B). Analyses of the genes (Figure 2C) related to liver metabolic diseases suggested that there was a homozygous mutation of the glucose 6-phosphatase catalytic (G6PC) gene on exon 5 (rs80356484), c.G648 T. This caused CTG to change to CTT (p. Leu216L) and created a new splicing site located 91 base pairs (bp) downstream of the authentic splice site. The patient’s parents were found to be heterozygous for c.G648 T. Therefore, the final clinical diagnosis for this patient was GSD Ia.

The patient was prescribed 50–100 g of raw corn starch four times a day (every 4–6 hours). After 9 months, the patient had grown by 10 cm in height, and secondary sexual characteristics had begun to develop, including facial hair, pubic hair, and seminal emission. However, Gd-EOB-DTPA MRI revealed that the diameter of the four lesions in segments II and III were larger than previously observed. In addition, two of the lesions were now hypointense, while in the previous hepatobiliary phase (HBP), they were hyperintense (Figure 3).

### Discussion

GSD Ia is a rare inherited metabolic disorder. Due to the lack of G6Pases, glucose 6-phosphates cannot be further hydrolysed into glucose, and thus excessive amounts of glycogen are accumulated. This leads to hepatomegaly (8).
Whole gene sequencing of the G6PC gene can be used to confirm the diagnosis of GSD Ia (9), which accounts for about 80% of GSD type I. Genetic mutations at certain sites of G6PC are related to different ethnic groups. For example, the mutation c.247C>T (p. Arg83Cys) has a high incidence in the Caucasian (32%) and Jewish (96%) communities, whereas the mutation of c.378_379dupTA (p. Tyr128Thrfs*3) is most common in the Hispanic population (50%). The genetic variation in our case study is a homozygous point mutation on exon V at the 17th chromosome (648G>T, p. Leu216L), and has a high prevalence in the Chinese (36–40%) and Japanese (85–88%).

Figure 2 Pathological examinations. (A) Periodic acid-Schiff (PAS) staining of the specimen showed a large amount of glycogen deposition in the hepatocytes (400× magnification). (B) Hematoxylin and eosin (HE) staining of the biopsy showed the presence of tumor cells (400× magnification). (C) The pathogenic mutation caused CTG to change to CTT in exon V at the 17th chromosome.

Figure 3 The gadolinium ethoxybenzyl-diethylenetriamine-pentaacetic acid magnetic resonance imaging (Gd-EOB-DTPA MRI) scans at the time of admission and at 9-month follow-up. (A,B) Scans taken on October 30th, 2016 at the time of admission and (C,D) scans taken on July 29, 2017 after 9 months of medical treatment. The lesion (white arrow, referred to as no. 4 adenoma in Table 1) presented with obvious enhancement in the arterial phase (A), and showed isointensity on hepatobiliary phase (HBP) in comparison with adjacent hepatocytes (B). After 9 months’ treatment, the diameter of the lesion (C) had grown larger in size compared to (A) and showed hypointensity on HBP (D).
Based on the molecular types of HCA, it can be classified into four subgroups with different imaging features, including hepatocyte nuclear factor 1A HCA (HHCA), inflammatory HCA (IHCA), activating β-catenin HCA (β-catenin HCA), and unclassified HCA (UHCA) (10). Approximately 16–75% of HCAs are associated with GSD type I (3). The signal intensity of HCAs varies on T1-weighted imaging (T1WI) and T2-weighted imaging (T2WI) MRI sequences, which may be explained by variations in adipose, hemorrhage, or glycogen deposition. Decreased signal intensity on T1WI opposed-phase images can be caused by intratumoral fat deposition presented in HHCA. The “atoll sign” (peripheral high signal intensity) on T2WI has been proposed to be a characteristic finding of IHCA (11). The obscure scar may be a possible sign of the BHCAs, but the specificity of these features remains very low (12). All types of HCAs show hypervascularization in the arterial phase. Different dynamic enhanced patterns, including wash-in, wash-out, and lasting enhancements, may be caused by different types of pathology. Generally, IHCA and β-catenin HCAs show lasting enhancement, while HHCA and UHCA show wash-in and wash-out patterns (11). HCAs typically appear hypointense on HBP which is also correlated with a low level of organic anion transporting polypeptide (OATP) expression. Yet, several studies have reported HCAs showing iso- or hyperintensity on HBP, especially in IHCA and BHCAs (13). This may be related to the uptake of the contrast agent due to the overexpression of OATP. Secondly, it may be explained by the combination of tumor hyperintensity on precontrast T1WI and underlying steatosis (12).

It is worth noting that this disease should be differentiated from focal nodular hyperplasia (FNH), a highly differentiated HCC. While HCAs are easily confused with FNH, the treatments for HCAs and FNH are different. The majority of FNH cases only require follow-up observation, whereas HCAs require clinical intervention. Approximately 90% of FNH and some HCA cases show hyperintensity in the HBP. The signal of FNH on T2WI imaging is close to that of normal liver parenchyma and often associated with a central scar (14). Intratumoral fat deposition and the atoll sign are typical features in HCAs but seldom observed in FNH (11). Reizine and colleagues reported that the mean liver-to-lesion contrast enhancement ratio (LLCER) of FNH was significantly higher than that of HCAs (46.67%±26.58% and 22.14%±30.74%, respectively) (15). Clinical symptoms such as obesity, metabolic diseases, and the use of oral contraceptives or steroids, will increase the confidence in the diagnosis of HCAs. Also, attention should be given to the differential diagnosis of HCCs, as 10% of highly differentiated HCCs also show hyperintensity in the HBP, which may be related to the overexpression of OATP on the surface of cancer cells. However, a low signal ring can be observed around the HCCs, and the signal of HCCs in the HBP is mostly heterogeneous, which presents as “mosaic” or “nodule-in-nodule” appearance (16). Moreover, HCC patients have a history of hepatitis with increased alphafetoprotein or abnormal prothrombin level (17).

Unfortunately, HCAs may progress to malignant transformations even if clinical symptoms improve after treatment. It has been reported that 5% of HCAs are associated with a risk of malignant transformation, especially β-catenin HCAs (18). Compared with HCAs induced by oral contraceptives or steroids, GSD I HCAs show a higher potential to transform into HCCs (19), but the pathological mechanism for this unclear. Kishnani et al. (20) used a high-density single-nucleotide polymorphism (SNP) array to evaluate chromosomal aberrations in 10 cases of GSD I HCAs and 7 cases of the general HCA population. The authors speculated that the chromosomal loss of 6q and the gain of 6p is significant for the malignant transformation of GSD Ia HCAs, which suggests that a regular diet alone may not prevent malignant transformation.

In conclusion, for childhood patients presenting with hepatomegaly, growth retardation, and laboratory tests abnormalities including hypoglycaemia, hyperuricaemia, and hyperlipidaemia, a diagnosis of GSD should be considered. If T1WI, T2WI, and Gd-EOB-DTPA MRI detect multiple masses with different signal intensities and enhancement patterns, there is a strong likelihood that the patient has GSD I with multiple HCAs. Treatment should be commenced without delay, even before gene sequencing analyses and liver biopsies are performed.

Acknowledgments

The authors are grateful to the patient and his family for their kind cooperation.

Funding: This study was supported by funding from the Research and Development of New Technology for Accurate Diagnosis and Treatment of Liver Tumor based on Magnetic Resonance Imaging - Specific Imaging and its Application in Central Hospitals in Northeast and Southwest Chongqing (csct2019jsx-
msxmX0200); Intelligent Assisted Diagnostic Model of Vascular Cognitive Dysfunction based on MRI Imaging Groupology (estc2019jscx-msxmX0104); Nursery Talents of Army Medical University (2017MPRC-07); The Army Medical University's Defense Innovation Program (2018XLC3008 rTMS); and the Military Medical Innovation Ability Improvement Plan of Medical Staff in the First Affiliated Hospital to Army Medical University (SWH2018QNWQ-04).

Footnote

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/qims-20-746). The authors have no conflicts of interest to declare.

Ethical Statement: Approval from the institutional review board and ethics committee was obtained prior to the study. The patient and his parents agreed that his clinical data can be used for research and publication.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


